Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

Smoking Cessation Clinical Trial

Official title:

Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01699828
• Other study ID #: 186/2011
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: October 2, 2012
• Last updated: June 3, 2014
• Start date: October 2012
• Est. completion date: June 2014

Study information

• Verified date: June 2014
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The objective of the present study is to use positron emission tomography brain imaging to investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that clinically relevant doses of buspirone will occupy the D3 receptor.

Description:

Buspirone is used for anxiety disorder treatment, a therapeutic effect that has been thought to be mediated through its partial agonist properties at the serotonin receptor. However, since one PET study in humans has shown low occupancy of the serotonin by buspirone in clinical doses and since the DRD3 has been recently implicated in anxiety, some therapeutic effects of buspirone may be mediated through the DRD3. In human clinical studies, promising effects of buspirone have been reported for treatment of substance dependence, including tobacco, marijuana, and opiates, and clinical studies in cocaine dependent subjects are underway. However, it is unclear if buspirone is producing those effects through the DRD3 and no human study has incorporated a PET imaging component to investigate this question; it remains unclear whether buspirone significantly occupies the DRD3 at therapeutic doses in humans.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• 19 years or older

Exclusion Criteria:

• Medical condition including cardiovascular, renal, hepatic or cerebrovascular diseases

• History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor, - Present or past psychiatric condition including mood, anxiety, psychotic disorders and substance abuse and/or dependence.

• Condition that precludes use of buspirone or that will interfere with participation in the present study (such as hypersensitive to buspirone hydrochloride).

• Pregnancy or breastfeeding.

• Presence of metal objects in the body or implanted electronic devices, that preclude safe MR scanning.

• Claustrophobia.

• Current use or use during the previous month of medication that may affect the CNS, including monoamine oxidase inhibitor (MAOI) or positive during drug screening for drugs of abuse or any medication that could increase the risk of buspirone administration.

• Exposure to radiation in the last 12 month exceeding permissible limit for subjects participating in research.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Smoking Cessation
• Tobacco Use Cessation

Intervention

Drug:
• Buspirone
The buspirone will be given once as a tablet and encapsulated for blinding.
• Placebo
Placebo will be lactose and encapsulated for blinding. A single capsule will be given.

Locations

Country	Name	City	State
Canada	Center for Addiction and Mental Health	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-response occupancy of buspirone at DRD3	[11C]-(+)-PHNO binding potential at three doses of buspirone and placebo.	few months	No

External Links

•   Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching